{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:21:35Z","timestamp":1790702495125,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,9,7]],"date-time":"2017-09-07T00:00:00Z","timestamp":1504742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,9,7]],"date-time":"2017-09-07T00:00:00Z","timestamp":1504742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Melanoma tumors are highly heterogeneous, comprising of different cell types that vary in their potential for growth and invasion. Heterogeneous expression of the Microphthalmia-associated Transcription Factor (MITF) and the POU domain transcription factor BRN2 (POU3F2) has been found in malignant melanoma. Changing expression of these transcription factors as the disease progresses has been linked to the metastatic mechanism of phenotype switching. We therefore investigated the effects of MITF and BRN2 expression in melanoma growth and metastasis. Depletion of MITF resulted in a cell population that had a slowed cell cycle progression, was less invasive <jats:italic>in vitro<\/jats:italic> and had hindered tumor and metastasis forming ability in mouse xenograft studies. BRN2 depletion left a cell population with intact proliferation and invasion <jats:italic>in vitro<\/jats:italic>; however metastatic growth was significantly reduced in the mouse xenograft model. These results suggest that the proliferative population within melanoma tumors express MITF, and both MITF and BRN2 are important for metastatic growth <jats:italic>in vivo<\/jats:italic>. This finding highlights the importance of BRN2 and MITF expression in development of melanoma metastasis.<\/jats:p>","DOI":"10.1038\/s41598-017-11366-y","type":"journal-article","created":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T14:26:15Z","timestamp":1504275975000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["MITF and BRN2 contribute to metastatic growth after dissemination of melanoma"],"prefix":"10.1038","volume":"7","author":[{"given":"Jacinta L.","family":"Simmons","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carly J.","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1553-0077","authenticated-orcid":false,"given":"Fares","family":"Al-Ejeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen M.","family":"Boyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,9,7]]},"reference":[{"key":"11366_CR1","doi-asserted-by":"publisher","first-page":"2951","DOI":"10.1038\/onc.2014.249","volume":"34","author":"A Roesch","year":"2015","unstructured":"Roesch, A. Tumor heterogeneity and plasticity as elusive drivers for resistance to MAPK pathway inhibition in melanoma. Oncogene \n                           34, 2951\u20132957 (2015).","journal-title":"Oncogene"},{"key":"11366_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ccell.2014.12.001","volume":"27","author":"N McGranahan","year":"2015","unstructured":"McGranahan, N. & Swanton, C. Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell \n                           27, 15\u201326 (2015).","journal-title":"Cancer Cell"},{"key":"11366_CR3","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1111\/j.1755-148X.2010.00757.x","volume":"23","author":"KS Hoek","year":"2010","unstructured":"Hoek, K. S. & Goding, C. R. Cancer stem cells versus phenotype-switching in melanoma. Pigment Cell Melanoma Res \n                           23, 746\u2013759 (2010).","journal-title":"Pigment Cell Melanoma Res"},{"key":"11366_CR4","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1158\/0008-5472.CAN-07-2491","volume":"68","author":"KS Hoek","year":"2008","unstructured":"Hoek, K. S. et al. In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res. \n                           68, 650\u2013656 (2008).","journal-title":"Cancer Res."},{"key":"11366_CR5","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.ccr.2010.10.012","volume":"18","author":"E Quintana","year":"2010","unstructured":"Quintana, E. et al. Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell \n                           18, 510\u2013523 (2010).","journal-title":"Cancer Cell"},{"key":"11366_CR6","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.cell.2010.04.020","volume":"141","author":"A Roesch","year":"2010","unstructured":"Roesch, A. et al. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell \n                           141, 583\u2013594 (2010).","journal-title":"Cell"},{"key":"11366_CR7","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/CMR.0b013e32833bd89e","volume":"20","author":"OM Eichhoff","year":"2010","unstructured":"Eichhoff, O. M. et al. The immunohistochemistry of invasive and proliferative phenotype switching in melanoma: a case report. Melanoma Res. \n                           20, 349\u2013355 (2010).","journal-title":"Melanoma Res."},{"key":"11366_CR8","doi-asserted-by":"publisher","first-page":"7788","DOI":"10.1158\/0008-5472.CAN-08-1053","volume":"68","author":"J Goodall","year":"2008","unstructured":"Goodall, J. et al. Brn-2 represses microphthalmia-associated transcription factor expression and marks a distinct subpopulation of microphthalmia-associated transcription factor-negative melanoma cells. Cancer Res. \n                           68, 7788\u20137794 (2008).","journal-title":"Cancer Res."},{"key":"11366_CR9","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/jid.2014.319","volume":"135","author":"ML Hartman","year":"2015","unstructured":"Hartman, M. L. & Czyz, M. Pro-survival role of MITF in melanoma. J. Invest. Dermatol. \n                           135, 352\u2013358 (2015).","journal-title":"J. Invest. Dermatol."},{"key":"11366_CR10","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1111\/pcmr.12370","volume":"28","author":"C Wellbrock","year":"2015","unstructured":"Wellbrock, C. & Arozarena, I. Microphthalmia-associated transcription factor in melanoma development and MAP-kinase pathway targeted therapy. Pigment Cell Melanoma Res \n                           28, 390\u2013406 (2015).","journal-title":"Pigment Cell Melanoma Res"},{"key":"11366_CR11","first-page":"691","volume":"11","author":"JA Thomson","year":"1995","unstructured":"Thomson, J. A. et al. The brn-2 gene regulates the melanocytic phenotype and tumorigenic potential of human melanoma cells. Oncogene \n                           11, 691\u2013700 (1995).","journal-title":"Oncogene"},{"key":"11366_CR12","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1111\/j.1755-148X.2008.00510.x","volume":"21","author":"AL Cook","year":"2008","unstructured":"Cook, A. L. & Sturm, R. A. POU domain transcription factors: BRN2 as a regulator of melanocytic growth and tumourigenesis. Pigment Cell Melanoma Res \n                           21, 611\u2013626 (2008).","journal-title":"Pigment Cell Melanoma Res"},{"key":"11366_CR13","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.yexcr.2005.04.019","volume":"308","author":"AL Cook","year":"2005","unstructured":"Cook, A. L., Smith, A. G., Smit, D. J., Leonard, J. H. & Sturm, R. A. Co-expression of SOX9 and SOX10 during melanocytic differentiation in vitro. Exp. Cell Res. \n                           308, 222\u2013235 (2005).","journal-title":"Exp. Cell Res."},{"key":"11366_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0002734","volume":"3","author":"C Wellbrock","year":"2008","unstructured":"Wellbrock, C. et al. Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF. PLoS One \n                           3, e2734 (2008).","journal-title":"PLoS One"},{"key":"11366_CR15","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1038\/onc.2011.33","volume":"30","author":"AE Thurber","year":"2011","unstructured":"Thurber, A. E. et al. Inverse expression states of the BRN2 and MITF transcription factors in melanoma spheres and tumour xenografts regulate the NOTCH pathway. Oncogene \n                           30, 3036\u20133048 (2011).","journal-title":"Oncogene"},{"key":"11366_CR16","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/j.1755-148X.2011.00849.x","volume":"24","author":"GM Boyle","year":"2011","unstructured":"Boyle, G. M. et al. Melanoma cell invasiveness is regulated by miR-211 suppression of the BRN2 transcription factor. Pigment Cell Melanoma Res \n                           24, 525\u2013537 (2011).","journal-title":"Pigment Cell Melanoma Res"},{"key":"11366_CR17","doi-asserted-by":"publisher","first-page":"7969","DOI":"10.1158\/0008-5472.CAN-09-0781","volume":"69","author":"S Pinner","year":"2009","unstructured":"Pinner, S. et al. Intravital imaging reveals transient changes in pigment production and Brn2 expression during metastatic melanoma dissemination. Cancer Res. \n                           69, 7969\u20137977 (2009).","journal-title":"Cancer Res."},{"key":"11366_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2015.00031","volume":"5","author":"FZ Li","year":"2015","unstructured":"Li, F. Z., Dhillon, A. S., Anderson, R. L., McArthur, G. & Ferrao, P. T. Phenotype switching in melanoma: implications for progression and therapy. front. Oncol. \n                           5, 31 (2015).","journal-title":"front. Oncol."},{"key":"11366_CR19","doi-asserted-by":"crossref","unstructured":"Arozarena, I. & Wellbrock, C. Targeting invasive properties of melanoma cells. FEBS J (2017).","DOI":"10.1111\/febs.14040"},{"key":"11366_CR20","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1038\/onc.2010.612","volume":"30","author":"T Strub","year":"2011","unstructured":"Strub, T. et al. Essential role of microphthalmia transcription factor for DNA replication, mitosis and genomic stability in melanoma. Oncogene \n                           30, 2319\u20132332 (2011).","journal-title":"Oncogene"},{"key":"11366_CR21","doi-asserted-by":"publisher","first-page":"3426","DOI":"10.1101\/gad.406406","volume":"20","author":"S Carreira","year":"2006","unstructured":"Carreira, S. et al. Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. Genes Dev. \n                           20, 3426\u20133439 (2006).","journal-title":"Genes Dev."},{"key":"11366_CR22","doi-asserted-by":"publisher","first-page":"3813","DOI":"10.1158\/0008-5472.CAN-09-2913","volume":"70","author":"S Giuliano","year":"2010","unstructured":"Giuliano, S. et al. Microphthalmia-associated transcription factor controls the DNA damage response and a lineage-specific senescence program in melanomas. Cancer Res. \n                           70, 3813\u20133822 (2010).","journal-title":"Cancer Res."},{"key":"11366_CR23","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1755-148X.2009.00653.x","volume":"23","author":"Y Cheli","year":"2010","unstructured":"Cheli, Y., Ohanna, M., Ballotti, R. & Bertolotto, C. Fifteen-year quest for microphthalmia-associated transcription factor target genes. Pigment Cell Melanoma Res \n                           23, 27\u201340 (2010).","journal-title":"Pigment Cell Melanoma Res"},{"key":"11366_CR24","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/j.1600-0749.2006.00322.x","volume":"19","author":"KS Hoek","year":"2006","unstructured":"Hoek, K. S. et al. Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res. \n                           19, 290\u2013302 (2006).","journal-title":"Pigment Cell Res."},{"key":"11366_CR25","volume":"3","author":"MR Eccles","year":"2013","unstructured":"Eccles, M. R. et al. MITF and PAX3 Play Distinct Roles in Melanoma Cell Migration; Outline of a \u201cGenetic Switch\u201d Theory Involving MITF and PAX3 in Proliferative and Invasive Phenotypes of Melanoma. Front. Oncol. \n                           3, 229 (2013).","journal-title":"Front. Oncol."},{"key":"11366_CR26","doi-asserted-by":"publisher","first-page":"4602","DOI":"10.1091\/mbc.E07-11-1137","volume":"19","author":"R Hu","year":"2008","unstructured":"Hu, R. & Aplin, A. E. Skp2 regulates G2\/M progression in a p53-dependent manner. Mol. Biol. Cell \n                           19, 4602\u20134610 (2008).","journal-title":"Mol. Biol. Cell"},{"key":"11366_CR27","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.3892\/mmr.2015.3569","volume":"12","author":"H Xue","year":"2015","unstructured":"Xue, H., Wang, Z., Chen, J., Yang, Z. & Tang, J. Knockdown of reticulon 4C by lentivirus inhibits human colorectal cancer cell growth. Mol Med Rep \n                           12, 2063\u20132067 (2015).","journal-title":"Mol Med Rep"},{"key":"11366_CR28","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.neo.2014.05.003","volume":"16","author":"R Ortenberg","year":"2014","unstructured":"Ortenberg, R. et al. CEACAM1 promotes melanoma cell growth through Sox-2. Neoplasia \n                           16, 451\u2013460 (2014).","journal-title":"Neoplasia"},{"key":"11366_CR29","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1111\/pcmr.12414","volume":"28","author":"N Ullrich","year":"2015","unstructured":"Ullrich, N. et al. MITF is a critical regulator of the carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) in malignant melanoma. Pigment Cell Melanoma Res \n                           28, 736\u2013740 (2015).","journal-title":"Pigment Cell Melanoma Res"},{"key":"11366_CR30","doi-asserted-by":"publisher","first-page":"12297","DOI":"10.18632\/oncotarget.3655","volume":"6","author":"H Cirenajwis","year":"2015","unstructured":"Cirenajwis, H. et al. Molecular stratification of metastatic melanoma using gene expression profiling: Prediction of survival outcome and benefit from molecular targeted therapy. Oncotarget \n                           6, 12297\u201312309 (2015).","journal-title":"Oncotarget"},{"key":"11366_CR31","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.ccr.2013.05.003","volume":"23","author":"A Roesch","year":"2013","unstructured":"Roesch, A. et al. Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell \n                           23, 811\u2013825 (2013).","journal-title":"Cancer Cell"},{"key":"11366_CR32","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1111\/j.1755-148X.2011.00893.x","volume":"24","author":"D Javelaud","year":"2011","unstructured":"Javelaud, D. et al. GLI2 and M-MITF transcription factors control exclusive gene expression programs and inversely regulate invasion in human melanoma cells. Pigment Cell Melanoma Res \n                           24, 932\u2013943 (2011).","journal-title":"Pigment Cell Melanoma Res"},{"key":"11366_CR33","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1128\/MCB.24.7.2915-2922.2004","volume":"24","author":"J Goodall","year":"2004","unstructured":"Goodall, J. et al. Brn-2 expression controls melanoma proliferation and is directly regulated by beta-catenin. Mol. Cell. Biol. \n                           24, 2915\u20132922 (2004).","journal-title":"Mol. Cell. Biol."},{"key":"11366_CR34","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1128\/MCB.24.7.2923-2931.2004","volume":"24","author":"J Goodall","year":"2004","unstructured":"Goodall, J. et al. The Brn-2 transcription factor links activated BRAF to melanoma proliferation. Mol. Cell. Biol. \n                           24, 2923\u20132931 (2004).","journal-title":"Mol. Cell. Biol."},{"key":"11366_CR35","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ccr.2010.10.029","volume":"19","author":"I Arozarena","year":"2011","unstructured":"Arozarena, I. et al. Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A. Cancer Cell \n                           19, 45\u201357 (2011).","journal-title":"Cancer Cell"},{"key":"11366_CR36","doi-asserted-by":"publisher","first-page":"10365","DOI":"10.1074\/jbc.M513094200","volume":"281","author":"GG McGill","year":"2006","unstructured":"McGill, G. G., Haq, R., Nishimura, E. K. & Fisher, D. E. c-Met expression is regulated by Mitf in the melanocyte lineage. J. Biol. Chem. \n                           281, 10365\u201310373 (2006).","journal-title":"J. Biol. Chem."},{"key":"11366_CR37","doi-asserted-by":"publisher","first-page":"4060","DOI":"10.1038\/sj.onc.1207563","volume":"23","author":"S Pavey","year":"2004","unstructured":"Pavey, S. et al. Microarray expression profiling in melanoma reveals a BRAF mutation signature. Oncogene \n                           23, 4060\u20134067 (2004).","journal-title":"Oncogene"},{"key":"11366_CR38","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1158\/0008-5472.CAN-06-4152","volume":"67","author":"M Stark","year":"2007","unstructured":"Stark, M. & Hayward, N. Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays. Cancer Res. \n                           67, 2632\u20132642 (2007).","journal-title":"Cancer Res."},{"key":"11366_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0026121","volume":"6","author":"VF Bonazzi","year":"2011","unstructured":"Bonazzi, V. F. et al. Cross-platform array screening identifies COL1A2, THBS1, TNFRSF10D and UCHL1 as genes frequently silenced by methylation in melanoma. PLoS One \n                           6, e26121 (2011).","journal-title":"PLoS One"},{"key":"11366_CR40","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/jid.2008.270","volume":"129","author":"GM Boyle","year":"2009","unstructured":"Boyle, G. M. et al. Macrophage inhibitory cytokine-1 is overexpressed in malignant melanoma and is associated with tumorigenicity. J. Invest. Dermatol. \n                           129, 383\u2013391 (2009).","journal-title":"J. Invest. Dermatol."},{"key":"11366_CR41","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nature10630","volume":"480","author":"S Yokoyama","year":"2011","unstructured":"Yokoyama, S. et al. A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature \n                           480, 99\u2013103 (2011).","journal-title":"Nature"},{"key":"11366_CR42","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.18632\/oncotarget.1143","volume":"4","author":"M Ohanna","year":"2013","unstructured":"Ohanna, M. et al. Secretome from senescent melanoma engages the STAT3 pathway to favor reprogramming of naive melanoma towards a tumor-initiating cell phenotype. Oncotarget \n                           4, 2212\u20132224 (2013).","journal-title":"Oncotarget"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-11366-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-11366-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-11366-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T10:36:27Z","timestamp":1671791787000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-11366-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,7]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["11366"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-11366-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,7]]},"assertion":[{"value":"16 January 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"10909"}}